| 750528 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P05.01 Organoid-specific optimization of killing assays to test novel immunotherapies in a high-throughput system |
2021-10-01 |
10.1136/jitc-2021-itoc8.34 |
van den Ham F, Kholosy WM, Ober K, Cornel AM, Nierkens S, Anderson J, Molenaar JJ, Wienke J |
| 750527 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P01.08 Sarcopenia as biomarker for immunotherapy outcomes and immune-related adverse events – a systematic review and meta-analysis |
2021-10-01 |
10.1136/jitc-2021-itoc8.12 |
Günther S, Trinkner P, von Bergwelt M, Cordas dos Santos D, Theurich S |
| 750526 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P07.01 A modular and controllable T cell therapy platform for AML |
2021-10-01 |
10.1136/jitc-2021-itoc8.42 |
Benmebarek M, Loureiro Cadilha B, Herrmann M, Schmitt S, Lesch S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Schwerdtfeger M, Gottschlich A, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner K, Kobold S, Rataj |
| 750525 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P06.01 αβ-T cells engineered to express γδ-T cell receptors can kill neuroblastoma organoids independent of MHC-I expression |
2021-10-01 |
10.1136/jitc-2021-itoc8.35 |
Strijker JGM, Drent E, van der Hoek JJF, Pscheid R, Koopmans B, Ober K, van Hooff SR, Kholosy WM, Coomans C, Bisso A, van Loenen M, Molenaar JJ, Wienke J |
| 750524 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P04.03 Expression profiles of immune markers as predictors of survival in surgically-treated NSCLC |
2021-10-01 |
10.1136/jitc-2021-itoc8.32 |
Sellmer L, Kovács J, Kumbrink J, Neumann J, Walter J, Kauffmann-Guerrero D, Schneider C, Tufman A |
| 750523 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P03.01 High immunogenic VLP-based vaccines elicit new T cell specificities against melanoma neoantigens in mice |
2021-10-01 |
10.1136/jitc-2021-itoc8.24 |
Aguilar-Gurrieri C, Barajas A, Pons-Grifols A, Varela I, Amengual-Rigo P, Farriol R, Vazquez M, Lepore R, Anjos-Souza C, Blanco-Heredia J, de Mattos-Arruda L, Guallar V, Valencia A, Clotet B, Carrillo J, Blanco J |
| 750522 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Author index |
2021-10-01 |
10.1136/jitc-2021-itoc8.authorindex |
|
| 750521 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P03.07 Analysis of scRNAseq from the human thymus nominates genes potentially missing from central tolerance of cytotoxic T cells |
2021-10-01 |
10.1136/jitc-2021-itoc8.29 |
Blumenberg L, Atwal G, Dhanik A |
| 750520 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P09.01 The use of FDA approved JAK, mTOR and Src inhibitors to regulate T cell-bispecific antibody-induced cytokine release while not preventing T cell cytotoxicity |
2021-10-01 |
10.1136/jitc-2021-itoc8.51 |
Leclercq G, Haegel H, Schneider A, Giusti A, Pulko V, Toso A, Zimmermann T, Green L, Steinhoff N, Sam J, Bacac M, Umaña P, Klein C |
| 750519 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P06.04 Transcriptome-wide network analysis predicts the role of lactate dehydrogenase C in breast cancer cell survival and immune dysfunction |
2021-10-01 |
10.1136/jitc-2021-itoc8.38 |
Naik A, Decock J |
